JP2018518990A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018518990A5 JP2018518990A5 JP2018517487A JP2018517487A JP2018518990A5 JP 2018518990 A5 JP2018518990 A5 JP 2018518990A5 JP 2018517487 A JP2018517487 A JP 2018517487A JP 2018517487 A JP2018517487 A JP 2018517487A JP 2018518990 A5 JP2018518990 A5 JP 2018518990A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- nucleic acid
- polypeptide
- acid molecule
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022044885A JP7460675B2 (ja) | 2015-06-19 | 2022-03-22 | Ｐｄ－１－ｃｄ２８融合タンパク質および医療におけるその使用 |
| JP2024044396A JP2024073636A (ja) | 2015-06-19 | 2024-03-21 | Ｐｄ－１－ｃｄ２８融合タンパク質および医療におけるその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15172913 | 2015-06-19 | ||
| EP15172913.4 | 2015-06-19 | ||
| PCT/EP2016/064195 WO2016203048A1 (en) | 2015-06-19 | 2016-06-20 | Pd-1-cd28 fusion proteins and their use in medicine |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022044885A Division JP7460675B2 (ja) | 2015-06-19 | 2022-03-22 | Ｐｄ－１－ｃｄ２８融合タンパク質および医療におけるその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018518990A JP2018518990A (ja) | 2018-07-19 |
| JP2018518990A5 true JP2018518990A5 (enExample) | 2019-06-06 |
| JP7085988B2 JP7085988B2 (ja) | 2022-06-17 |
Family
ID=53476720
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018517487A Active JP7085988B2 (ja) | 2015-06-19 | 2016-06-20 | Ｐｄ－１－ｃｄ２８融合タンパク質および医療におけるその使用 |
| JP2022044885A Active JP7460675B2 (ja) | 2015-06-19 | 2022-03-22 | Ｐｄ－１－ｃｄ２８融合タンパク質および医療におけるその使用 |
| JP2024044396A Pending JP2024073636A (ja) | 2015-06-19 | 2024-03-21 | Ｐｄ－１－ｃｄ２８融合タンパク質および医療におけるその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022044885A Active JP7460675B2 (ja) | 2015-06-19 | 2022-03-22 | Ｐｄ－１－ｃｄ２８融合タンパク質および医療におけるその使用 |
| JP2024044396A Pending JP2024073636A (ja) | 2015-06-19 | 2024-03-21 | Ｐｄ－１－ｃｄ２８融合タンパク質および医療におけるその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11192935B2 (enExample) |
| EP (3) | EP3909972B1 (enExample) |
| JP (3) | JP7085988B2 (enExample) |
| CN (3) | CN115927474A (enExample) |
| AU (1) | AU2016277883B2 (enExample) |
| CA (1) | CA2989949A1 (enExample) |
| DK (2) | DK3909972T5 (enExample) |
| ES (2) | ES2870174T3 (enExample) |
| FI (1) | FI3909972T3 (enExample) |
| HU (1) | HUE054201T2 (enExample) |
| PL (1) | PL3310805T3 (enExample) |
| PT (1) | PT3310805T (enExample) |
| WO (1) | WO2016203048A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201707182WA (en) | 2015-03-05 | 2017-10-30 | Hutchinson Fred Cancer Res | Immunomodulatory fusion proteins and uses thereof |
| EP3770168A1 (en) | 2015-05-18 | 2021-01-27 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| PT3310805T (pt) * | 2015-06-19 | 2021-05-19 | Kobold Sebastian | Proteínas de fusão pd-1-cd28 e a sua utilização em medicina |
| MX2018000278A (es) * | 2015-06-29 | 2018-03-08 | Univ Johns Hopkins | Terapia de receptores quimericos de puntos de control inmunitarios. |
| CN105331585A (zh) * | 2015-11-13 | 2016-02-17 | 科济生物医药（上海）有限公司 | 携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞 |
| US11365237B2 (en) * | 2016-03-23 | 2022-06-21 | Helmholtz Zentrum Muenchen—Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) | Fusion proteins of PD-1 and 4-1BB |
| CN107523545A (zh) * | 2016-06-20 | 2017-12-29 | 上海细胞治疗研究院 | 一种高效稳定表达抗体的杀伤性细胞及其用途 |
| EP3478722A1 (en) * | 2016-06-30 | 2019-05-08 | F. Hoffmann-La Roche AG | Improved adoptive t-cell therapy |
| WO2018026953A1 (en) | 2016-08-02 | 2018-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| BR112019007100A2 (pt) | 2016-10-07 | 2019-06-25 | Tcr2 Therapeutics Inc | composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão |
| CN110177803A (zh) | 2016-11-22 | 2019-08-27 | T细胞受体治疗公司 | 用于使用融合蛋白进行tcr重新编程的组合物和方法 |
| CA3047999A1 (en) * | 2016-12-21 | 2018-06-28 | TCR2 Therapeutics Inc. | Engineered t cells for the treatment of cancer |
| US11535662B2 (en) * | 2017-01-26 | 2022-12-27 | Novartis Ag | CD28 compositions and methods for chimeric antigen receptor therapy |
| US11725210B2 (en) | 2017-03-17 | 2023-08-15 | Fred Hutchinson Cancer Center | Immunomodulatory fusion proteins and uses thereof |
| KR20200130709A (ko) * | 2018-03-06 | 2020-11-19 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 전립선-특이 막 항원 car 및 이의 사용 방법 |
| CN108727504B (zh) * | 2018-04-16 | 2021-08-27 | 泉州向日葵生物科技有限公司 | 一种ifn与抗pd-l1抗体的融合蛋白及其应用 |
| CN111606999B (zh) * | 2019-02-26 | 2022-09-06 | 南京惟亚德生物医药有限公司 | 兼具激活免疫共刺激信号通路和阻断免疫检查点的复制型溶瘤腺病毒及其应用 |
| TW202042824A (zh) | 2019-03-27 | 2020-12-01 | 賓夕法尼亞大學董事會 | Tn-MUC1嵌合抗原受體（CAR）T細胞療法 |
| EP3999079A4 (en) * | 2019-07-19 | 2024-04-03 | Memorial Sloan Kettering Cancer Center | Fusion polypeptide for immunotherapy |
| CN113832114A (zh) * | 2020-06-23 | 2021-12-24 | 南京大学 | 一种新型溶瘤腺病毒EM/VSV-G Ad5-P及其在制备抗肿瘤药物中的应用 |
| CN113832111A (zh) * | 2020-06-23 | 2021-12-24 | 南京大学 | 一种类外泌体技术用于制备新型溶瘤病毒的方法 |
| EP4305174A4 (en) * | 2021-03-10 | 2025-04-30 | B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University | REPORTER CELLS EXPRESSING CHIMERIC POLYPEPTIDES TO DETERMINE THE PRESENCE AND/OR ACTIVITY OF IMMUNE CHECKPOINT MOLECULES |
| CN115197314B (zh) * | 2021-04-11 | 2025-08-19 | 中国科学院分子细胞科学卓越创新中心 | 一种pd1变体及其用途 |
| JP2024519945A (ja) * | 2021-05-20 | 2024-05-21 | アチェロイス バイオファーマ，インク． | 免疫チェックポイント多価粒子の組成物、および使用方法 |
| WO2023235479A1 (en) * | 2022-06-02 | 2023-12-07 | TCR2 Therapeutics Inc. | Compositions and methods for treating cancer |
| EP4619424A2 (en) * | 2022-11-14 | 2025-09-24 | Achelois Biopharma, Inc. | Immune checkpoint multivalent particles compositions and methods of use |
| WO2025212859A1 (en) * | 2024-04-03 | 2025-10-09 | Solid Biosciences, Inc. | Methods and constructs for increasing solid organ transplant survival |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19822115B4 (de) | 1998-05-08 | 2004-04-08 | Heinrich-Pette-Institut | Retrovirale Gentransfervektoren |
| CN101287831B (zh) | 2005-09-13 | 2013-05-15 | 国立大学法人三重大学 | T细胞受体和编码该受体的核酸 |
| EP2318434A1 (en) | 2008-07-31 | 2011-05-11 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Her2/neu specific t cell receptors |
| ZA200807283B (en) | 2008-08-22 | 2009-10-28 | Mechlift Invest Pty Ltd | Data unit for a bin lifting device |
| AU2009290543B2 (en) | 2008-09-12 | 2015-09-03 | Oxford University Innovation Limited | PD-1 specific antibodies and uses thereof |
| CN103119054B (zh) * | 2010-03-26 | 2017-01-18 | 达特茅斯大学理事会 | Vista调节性t细胞介体蛋白、vista结合剂及其用途 |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| EP3459560B1 (en) | 2011-04-08 | 2021-02-24 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer |
| MX2014001222A (es) * | 2011-07-29 | 2014-09-15 | Univ Pennsylvania | Receptores coestimuladores de cambio. |
| JP6267644B2 (ja) | 2011-10-20 | 2018-01-24 | アメリカ合衆国 | 抗ｃｄ２２キメラ抗原受容体 |
| WO2013062365A2 (ko) * | 2011-10-26 | 2013-05-02 | 국립암센터 | 변이 ｃｔｌａ4 유전자 이입 ｔ 세포 및 이를 포함하는 항암 면역치료용 조성물 |
| JP6074435B2 (ja) * | 2011-10-26 | 2017-02-01 | ナショナル キャンサー センター | 変異ｃｔｌａ４遺伝子移入ｔ細胞及びこれを含む抗がん免疫治療用組成物 |
| CA2868121C (en) | 2012-03-23 | 2021-06-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mesothelin chimeric antigen receptors |
| AU2013246443B2 (en) | 2012-04-11 | 2017-04-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting B-cell maturation antigen |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| US10117896B2 (en) | 2012-10-05 | 2018-11-06 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| US9657105B2 (en) | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| JP6285553B2 (ja) | 2013-08-26 | 2018-02-28 | インノバイオファーム リミテッド | 抗ｃｄ３０キメラ抗原受容体およびその使用 |
| EP3227317A4 (en) | 2014-12-02 | 2018-04-25 | Roger Williams Hospital | Methods and compositons for treating cancer |
| SG11201707182WA (en) | 2015-03-05 | 2017-10-30 | Hutchinson Fred Cancer Res | Immunomodulatory fusion proteins and uses thereof |
| PT3310805T (pt) | 2015-06-19 | 2021-05-19 | Kobold Sebastian | Proteínas de fusão pd-1-cd28 e a sua utilização em medicina |
| JP6974311B2 (ja) | 2015-06-23 | 2021-12-01 | メモリアル スローン ケタリング キャンサー センター | 新規ｐｄ−１免疫調節剤 |
| MX2018000278A (es) | 2015-06-29 | 2018-03-08 | Univ Johns Hopkins | Terapia de receptores quimericos de puntos de control inmunitarios. |
| US11242375B2 (en) | 2015-09-04 | 2022-02-08 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of use |
| US11020429B2 (en) | 2015-11-05 | 2021-06-01 | Juno Therapeutics, Inc. | Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy |
| CN105331585A (zh) | 2015-11-13 | 2016-02-17 | 科济生物医药（上海）有限公司 | 携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞 |
| CN109072194B (zh) | 2015-12-09 | 2022-12-27 | 纪念斯隆-凯特林癌症中心 | 免疫细胞组合物及其使用方法 |
| US11365237B2 (en) | 2016-03-23 | 2022-06-21 | Helmholtz Zentrum Muenchen—Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) | Fusion proteins of PD-1 and 4-1BB |
| WO2018119198A1 (en) | 2016-12-22 | 2018-06-28 | Windmil Therapeutics, Inc. | Compositions and methods for modulating the immune system |
| CN111051349A (zh) | 2017-09-06 | 2020-04-21 | 弗雷德哈钦森癌症研究中心 | Strep-tag特异性嵌合受体及其用途 |
| CN115418362B (zh) * | 2019-12-02 | 2025-06-13 | 吉林凯莱英医药化学有限公司 | 共固定化酶、其制备方法及其应用 |
-
2016
- 2016-06-20 PT PT167368026T patent/PT3310805T/pt unknown
- 2016-06-20 CN CN202210834160.0A patent/CN115927474A/zh active Pending
- 2016-06-20 DK DK21155542.0T patent/DK3909972T5/da active
- 2016-06-20 FI FIEP21155542.0T patent/FI3909972T3/fi active
- 2016-06-20 ES ES16736802T patent/ES2870174T3/es active Active
- 2016-06-20 US US15/737,877 patent/US11192935B2/en active Active
- 2016-06-20 JP JP2018517487A patent/JP7085988B2/ja active Active
- 2016-06-20 EP EP21155542.0A patent/EP3909972B1/en active Active
- 2016-06-20 CN CN201680048221.3A patent/CN108026151B/zh active Active
- 2016-06-20 AU AU2016277883A patent/AU2016277883B2/en active Active
- 2016-06-20 CA CA2989949A patent/CA2989949A1/en active Pending
- 2016-06-20 CN CN202210854297.2A patent/CN115925971A/zh active Pending
- 2016-06-20 ES ES21155542T patent/ES2976647T3/es active Active
- 2016-06-20 WO PCT/EP2016/064195 patent/WO2016203048A1/en not_active Ceased
- 2016-06-20 EP EP24156660.3A patent/EP4349854A3/en active Pending
- 2016-06-20 EP EP16736802.6A patent/EP3310805B1/en active Active
- 2016-06-20 PL PL16736802T patent/PL3310805T3/pl unknown
- 2016-06-20 DK DK16736802.6T patent/DK3310805T3/da active
- 2016-06-20 HU HUE16736802A patent/HUE054201T2/hu unknown
-
2021
- 2021-10-29 US US17/515,250 patent/US12570718B2/en active Active
-
2022
- 2022-03-22 JP JP2022044885A patent/JP7460675B2/ja active Active
-
2024
- 2024-03-21 JP JP2024044396A patent/JP2024073636A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI840351B (zh) | T細胞受體及表現其之工程化細胞 | |
| JP7452880B2 (ja) | Ｓｓｘ２抗原を識別するｔ細胞受容体 | |
| US20210363258A1 (en) | Hpv-specific binding molecules | |
| CN106414748B (zh) | 嵌合抗原受体及制备方法 | |
| Tynan et al. | High resolution structures of highly bulged viral epitopes bound to major histocompatibility complex class I: implications for T-cell receptor engagement and T-cell immunodominance | |
| JP7146397B2 (ja) | 改変γδＴ細胞 | |
| EP3024468B1 (en) | T cell receptors | |
| CN112673022A (zh) | 针对cd33的单结构域抗体及其构建体 | |
| JP2017537627A5 (enExample) | ||
| CN110177808A (zh) | 针对axl或ror2的嵌合抗原受体及其使用方法 | |
| JP2019516663A5 (enExample) | ||
| JP2017535292A5 (enExample) | ||
| FI3909972T3 (fi) | Pd1-cd28-fuusioproteiineja ja niiden käyttö lääkkeessä | |
| BR112021008133A2 (pt) | Métodos para seleção e estimulação de células e aparelhos para os mesmos | |
| KR20190016960A (ko) | γδ T-세포 집단의 선택적 확장을 위한 방법 및 그의 조성물 | |
| JP2016534717A5 (enExample) | ||
| JP2017538401A5 (enExample) | ||
| JP2019512251A5 (enExample) | ||
| US20250283037A1 (en) | Methods for stimulating and transducing t cells | |
| EP4051402B1 (en) | Cell selection and/or stimulation devices and methods of use | |
| JP7429455B2 (ja) | Ａｆｐ抗原を識別するｔ細胞受容体 | |
| KR20230013257A (ko) | 종양 미세환경의 역전을 위한 융합 단백질 및 이의 응용 | |
| CA3140064A1 (en) | Lockr-mediated recruitment of car t cells | |
| KR20230012465A (ko) | 암 및 관련 악성 종양을 치료하기 위해 t 세포를 확장하는 방법 | |
| CN108085340A (zh) | 一种同时表达靶向cd19和cd20的car与pd1-cd28嵌合受体的慢病毒载体 |